Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

  • Jesús Troya,
  • Pablo Ryan,
  • Esteban Ribera,
  • Daniel Podzamczer,
  • Victor Hontañón,
  • Jose Alberto Terrón,
  • Vicente Boix,
  • Santiago Moreno,
  • Pilar Barrufet,
  • Manuel Castaño,
  • Ana Carrero,
  • María José Galindo,
  • Ignacio Suárez-Lozano,
  • Hernando Knobel,
  • Miguel Raffo,
  • Javier Solís,
  • María Yllescas,
  • Herminia Esteban,
  • Juan González-García,
  • Juan Berenguer,
  • Arkaitz Imaz,
  •  [ ... ],
  • GESIDA-8314 Study Group
  • [ view all ]
  • [ view less ]
  • Article
  • Metrics
  • Comments
  • Media Coverage

The affiliation of the author Juan Berenguer is incorrect. The correct affiliation is: Hospital Universitario Gregorio Marañón, Madrid, Spain.

Reference

  1. 1. Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, et al. (2016) Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS ONE 11(10): e0164455. pmid:27727331

Citation: Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, et al. (2017) Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS ONE 12(2): e0172184. https://doi.org/10.1371/journal.pone.0172184

Published: February 9, 2017

Copyright: © 2017 Troya et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.